Clinical Phenotype “Obesity-Asthma” as One of the Main Problems of Personalized Pulmonology

ORIGINAL ARTICLE
Ludmila V. Tribuntceva, Yanina S. Shkatova, Sergey N. Avdeev, Andrey V. Budnevsky, Evgeniy S. Ovsyannikov

 
International Journal of Biomedicine. 2019;9(2):117-120.
DOI: 10.21103/Article9(2)_OA6
Originally published June 15, 2019  

Abstract: 

Background: Asthma is a heterogeneous disease comprising different phenotypes. One of the most common asthma phenotypes is the obesity-asthma phenotype, since obesity affects over a third of the world’s population today. It is important to continue investigating possible underlying mechanisms of the interaction between asthma and obesity. The purpose of this study was to evaluate levels of leptin, adiponectin, neuropeptide Y (NPY), total oxidative damage (TOD), and total antioxidant status (TAS) in patients with asthma and different body weight (BW), and to analyze their association with spirometry parameters.
Materials and Methods: The study included 27 men and 86 women diagnosed with moderate asthma aged from 18 to 75 years (mean age of 57.81±13.05 years). During the study, all asthma patients were divided into 3 groups. Group 1 included 37 patients with normal BW, Group 2 included 38 overweight patients, and Group 3 included 38 patients with obesity. We analyzed complaints, anamnesis data, objective status data, and laboratory (levels of NPY, adiponectin, leptin, total antioxidant status, and total oxidative damage) and instrumental data (spirometry). Two questionnaires were used: Asthma Quality of Life Questionnaire (AQLQ) and Asthma Control Test (АСТ).
 Results: The leptin level was significantly higher in Group 3 compared to Groups 1 and 2 (P=0.0000). The NPY level was significantly lower in Group 1 compared to Groups 2 and 3 (P=0.0000). The TAS value was significantly higher in Group 1 compared to Groups 2 and 3 (P=0.0000) and the TOD value in Group 1 was significantly lower than in Group 3 (P=0.0382). The leptin level positively correlated with BMI and waist circumference, and had an inverse correlation with FEV1 and vital capacity (VC). The adiponectin level had a positive correlation with the Tiffno index, FEF50, and peak expiratory flow (PEF). The NPY level had an inverse correlation with VC, FEV1, FEF25, FVC, Tiffno index, FEF50, and PEF.
Conclusion: The severity of the clinical course of moderate asthma in obese patients is associated with different factors, including oxidative stress and levels of leptin, adiponectin and NPY.

Keywords: 
asthma • body weight • oxidative stress • leptin • adiponectin • neuropeptide Y
References: 
  1. Budnevsky AV, Tribuntceva LV, Kozhevnikova SA, Ovsyannikov ES. Impact of metabolic syndrome components on asthma control and life quality of patients. International Journal of Biomedicine. 2018;8(1):33-36. doi: 10.21103/article8(1)_OA4.
  2. Budnevsky AV, Malysh EY, Ovsyannikov ES, Drobysheva ES. [Asthma and metabolic syndrome: Clinical and pathogenetic relationships]. Ter Arkh. 2015;87(10):110-114. doi: 10.17116/terarkh20158710110-114. [Article in Russian].
  3. Tsvetikova LN, Budnevsky AV, Ovsyannikov ES, Kudashova EA. [Melatonin: Possibilities for use in the treatment of asthma]. Ter Arkh. 2017;89(3):112-115. doi: 10.17116/terarkh2017893112-115. [Article in Russian].
  4. Provotorov VM, Budnevsky AV, Filatova YI. [Clinical manifestations of asthma during combination therapy using ceruloplasmin]. Ter Arkh. 2016;88(3):36-39. doi: 10.17116/terarkh201688336-39. [Article in Russian].
  5. Hirose M, Horiguchi T. Asthma phenotypes. J Gen Fam Med. 2017;18(5):189-194. doi: 10.1002/jgf2.7.
  6. Matsusaka M, Fukunaga K, Kabata H, Izuhara K, Asano K, Betsuyaku T. Subphenotypes of type 2 severe asthma in adults. J Allergy Clin Immunol Pract. 2018;6(1):274-276.e2. doi: 10.1016/j.jaip.2017.06.015.
  7. Zacharias J, Ishmael FT, Henao M, Rael EL. Identification of Sub-Phenotypes of Eosinophilic Asthma: Eosinophilic Asthma Is Not Always Allergic Asthma. The Journal of Allergy and Clinical Immunology. 2017;139(2):AB170. doi: 10.1016/j.jaci.2016.12.557.
  8. Hruby A, Hu FB.The Epidemiology of Obesity: A Big Picture. Pharmacoeconomics. 2015;33(7):673-89. doi: 10.1007/s40273-014-0243-x.
  9. Global strategy for asthma management and prevention (GINA, 2017 REPORT). Available from: file:///C:/Users/Admin/Downloads/wmsGINA-2017-main-report-final_V2%20(1).pdf
  10. Ruhl CE, Everhart JE. Leptin concentrations in the United States: relations with demographic and anthropometric measures. Am J Clin Nutr. 2001;74(3):295-301.doi: 10.1093/ajcn/74.3.295.
  11. Vuolteenaho K, Koskinen A, Kukkonen M, Nieminen R, Päivärinta U, Moilanen T, et al. Leptin enhances synthesis of proinflammatory mediators in human osteoarthritic cartilage--mediator role of NO in leptin-induced PGE2, IL-6, and IL-8 production. Mediators Inflamm. 2009;2009:345838. doi: 10.1155/2009/345838.
  12. Sood A, Ford ES, Camargo CA Jr. Association between leptin and asthma in adults. Thorax. 2006;61(4):300-5. doi: 10.1136/thx.2004.031468.
  13. Sood A, Cui X, Qualls C, Beckett WS, Gross MD, Steffes MW, et al. Association between asthma and serum adiponectin concentration in women. Thorax. 2008;63(10):877-82. doi: 10.1136/thx.2007.090803.
  14. Nagel G, Koenig W, Rapp K, Wabitsch M, Zoellner I, Weiland SK. Associations of adipokines with asthma, rhinoconjunctivitis, and eczema in German schoolchildren. Pediatr Allergy Immunol. 2009;20(1):81-8. doi: 10.1111/j.1399-3038.2008.00740.x.
  15. Jartti T, Saarikoski L, Jartti L, Lisinen I, Jula A, Huupponen R, et al. Obesity, adipokines and asthma. Allergy. 2009;64(5):770-7. doi: 10.1111/j.1398-9995.2008.01872.x.
  16. Sutherland TJ, Sears MR, McLachlan CR, Poulton R, Hancox RJ. Leptin, adiponectin, and asthma: findings from a population-based cohort study. Ann Allergy Asthma Immunol. 2009;103(2):101-7. doi: 10.1016/S1081-1206(10)60161-5.
  17. Sood A, Dominic E, Qualls C, Steffes MW, Thyagarajan B, Smith LJ, et al. Serum Adiponectin is Associated with Adverse Outcomes of Asthma in Men but Not in Women. Front Pharmacol. 2011;2:55. doi:10.3389/fphar.2011.00055.
  18. Tsaroucha A, Daniil Z, Malli F, Georgoulias P, Minas M, Kostikas K, et al. Leptin, adiponectin, and ghrelin levels in female patients with asthma during stable and exacerbation periods. J Asthma. 2013;50(2):188-97. doi: 10.3109/02770903.2012.747101.
  19. Sideleva O, Suratt BT, Black KE, Tharp WG, Pratley RE, Forgione P, et al. Obesity and asthma: an inflammatory disease of adipose tissue not the airway. Am J Respir Crit Care Med. 2012;186(7):598-605. doi: 10.1164/rccm.201203-0573OC.
  20. Pihl E, Zilmer K, Kullisaar T, Kairane C, Mägi A, Zilmer M. Atherogenic inflammatory and oxidative stress markers in relation to overweight values in male former athletes. Int J Obes (Lond). 2006;30(1):141-6. doi: 10.1038/sj.ijo.0803068.
  21. Chrysohoou C, Panagiotakos DB, Pitsavos C, Skoumas I, Papademetriou L, Economou M, et al.The implication of obesity on total antioxidant capacity in apparently healthy men and women: the ATTICA study. Nutr Metab Cardiovasc Dis. 2007;17(8):590-7. doi: 10.1016/j.numecd.2006.05.007.
  22. Lu Y, Andiappan AK, Lee B, Ho R, Lim TK, Kuan WS, et al. Neuropeptide Y associated with asthma in young adults. Neuropeptides. 2016;59:117-121. doi: 10.1016/j.npep.2016.07.003.
  23. Jaakkola U, Kakko T, Juonala M, Lehtimäki T, Viikari J, Jääskeläinen AE, et al. Neuropeptide Y polymorphism increases the risk for asthma in overweight subjects; protection from atherosclerosis in asthmatic subjects--the cardiovascular risk in young Finns study. Neuropeptides. 2012;46(6):321-8. doi: 10.1016/j.npep.2012.09.005.
  24. Macia L, Rao PT, Wheway J, Sierro F, Mackay F, Herzog H. Y1 signalling has a critical role in allergic airway inflammation. Immunol Cell Biol. 2011;89(8):882-8. doi: 10.1038/icb.2011.6.
  25. Cardell LO, Uddman R, Edvinsson L. Low plasma concentrations of VIP and elevated levels of other neuropeptides during exacerbations of asthma. Eur Respir J. 1994;7(12):2169-73.

Download Article
Received April 11, 2019.
Accepted May 9, 2019.
©2019 International Medical Research and Development Corporation.